Overview

Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects

Status:
Completed

Trial end date:
2012-05-01

Target enrollment:

Participant gender:

Summary

Patients with HIV-1 infection on HAART regimen including 2 NRTI/NtRTIs plus one of the following : 1 PI/ritonavir or ATV/unboosted or 1 NNRTI, will be randomized to switch from the NNRTI/PI to maraviroc (300 mg /12 h) or to continue with the same approach.

Phase:

Phase 4

Details

Lead Sponsor:

Germans Trias i Pujol Hospital

Treatments:

Maraviroc
Protease Inhibitors
Reverse Transcriptase Inhibitors